See more : TYK Medicines Inc (2410.HK) Income Statement Analysis – Financial Results
Complete financial analysis of MicroPort CardioFlow Medtech Corporation (2160.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MicroPort CardioFlow Medtech Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
- KION GROUP AG (KNNGF) Income Statement Analysis – Financial Results
- Jiangxi Synergy Pharmaceutical Co., Ltd. (300636.SZ) Income Statement Analysis – Financial Results
- Polyplex Corporation Limited (POLYPLEX.NS) Income Statement Analysis – Financial Results
- Haber, Inc. (ASPT) Income Statement Analysis – Financial Results
- XPS Pensions Group plc (XPS.L) Income Statement Analysis – Financial Results
MicroPort CardioFlow Medtech Corporation (2160.HK)
About MicroPort CardioFlow Medtech Corporation
MicroPort CardioFlow Medtech Corporation, a medical device company, researches, develops, and commercializes transcatheter and surgical solutions for structural heart diseases in the People's Republic of China. It offers Vitaflow Aortic Valve System, Alwide Balloon Catheter, and Alpass Introducer Set to target aortic, mitral, tricuspid, and surgical valves, as well as procedural accessories. The company was founded in 2010 and is headquartered in Shanghai, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 336.22M | 251.03M | 200.81M | 103.93M | 21.50M | 0.00 |
| Cost of Revenue | 106.28M | 88.90M | 82.11M | 58.55M | 15.20M | 0.00 |
| Gross Profit | 229.93M | 162.13M | 118.70M | 45.38M | 6.30M | 0.00 |
| Gross Profit Ratio | 68.39% | 64.59% | 59.11% | 43.66% | 29.31% | 0.00% |
| Research & Development | 237.34M | 223.78M | 151.13M | 96.84M | 96.70M | 44.75M |
| General & Administrative | 70.22M | 71.99M | 41.24M | 98.95M | 2.89M | 1.49M |
| Selling & Marketing | 223.01M | 160.78M | 116.42M | 51.36M | 26.11M | 9.38M |
| SG&A | 293.23M | 232.77M | 157.66M | 150.30M | 28.99M | 10.87M |
| Other Expenses | 13.02M | -10.32M | -1.89M | -16.39M | 4.06M | 4.33M |
| Operating Expenses | 543.58M | 446.23M | 306.90M | 230.75M | 129.75M | 59.94M |
| Cost & Expenses | 649.87M | 535.13M | 389.01M | 289.31M | 144.95M | 59.94M |
| Interest Income | 86.54M | 38.64M | 24.71M | 5.22M | 60.00K | 1.08M |
| Interest Expense | 3.92M | 5.19M | 19.64M | 146.15M | 12.42M | 900.00K |
| Depreciation & Amortization | 73.62M | 78.22M | 44.42M | 24.50M | 13.76M | 59.94M |
| EBITDA | -386.05M | -347.91M | -126.43M | -227.43M | -118.34M | -56.55M |
| EBITDA Ratio | -114.82% | -93.77% | -62.96% | -156.53% | -505.22% | 0.00% |
| Operating Income | -401.84M | -284.10M | -188.20M | -185.37M | -123.45M | -59.26M |
| Operating Income Ratio | -119.52% | -113.18% | -93.72% | -178.36% | -574.13% | 0.00% |
| Total Other Income/Expenses | -61.74M | -74.72M | -2.84M | -212.71M | -21.07M | -320.00K |
| Income Before Tax | -463.58M | -451.30M | -182.65M | -398.09M | -144.52M | -60.26M |
| Income Before Tax Ratio | -137.88% | -179.78% | -90.96% | -383.02% | -672.13% | 0.00% |
| Income Tax Expense | 7.95M | 3.10M | 613.00K | 210.89M | 22.13M | 580.00K |
| Net Income | -471.53M | -454.40M | -183.26M | -608.98M | -166.65M | -60.26M |
| Net Income Ratio | -140.25% | -181.02% | -91.26% | -585.93% | -775.05% | 0.00% |
| EPS | -0.20 | -0.19 | -0.08 | -0.26 | -131.66 | -0.03 |
| EPS Diluted | -0.20 | -0.19 | -0.08 | -0.26 | -131.66 | -0.03 |
| Weighted Avg Shares Out | 2.36B | 2.37B | 2.33B | 2.37B | 1.27M | 2.37B |
| Weighted Avg Shares Out (Dil) | 2.36B | 2.37B | 2.33B | 2.37B | 1.27M | 2.37B |
Source: https://incomestatements.info
Category: Stock Reports